DCM
DNLI icon

Dupont Capital Management’s Denali Therapeutics DNLI Stock Holding History

Dupont Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,320
Closed -$193K – 1715
2021
Q4 		$193K Sell
4,320
-3,807
-47% -$180K 0.01% 1129
2021
Q3 		$410K Sell
8,127
-3,984
-33% -$225K 0.01% 964
2021
Q2 		$950K Buy
+12,111
New +$749K 0.02% 660

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Dupont Capital Management's DNLI Position: Q1 2022 in Review

Dupont Capital Management sold out of Denali Therapeutics (DNLI) in Q1 2022, closing a stake of 4,320 shares — an estimated $193K sold.

Dupont Capital Management first reported a position in DNLI in Q2 2021 and held it in 3 quarters. The position peaked at $950K in Q2 2021. 190 funds tracked by Wall St. Rank hold DNLI as of Q1 2022.

  • Dupont Capital Management reported no remaining Denali Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Dupont Capital Management sold 4,320 Denali Therapeutics shares in Q1 2022, an estimated $193K.
  • Dupont Capital Management first reported a position in Denali Therapeutics in Q2 2021 and held it in 3 quarters.
  • Dupont Capital Management's Denali Therapeutics position peaked at $950K in Q2 2021.
  • 190 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2022.

Based on Dupont Capital Management's 13F filing for Q1 2022, filed 27 Apr 2022.